New therapy combination yields high remission rates in early-stage Hodgkin lymphoma

Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine—according to a study published in Blood.